Abstract 1911P
Background
Mutations of the von Hippel-Lindau (VHL) tumor suppressor gene occur in the majority of sporadic renal-cell carcinomas (RCC). Certain VHL mutations correlate with low expression of classical HLA-I molecules and HLA-E expression that determine higher NK susceptibility. Therefore, VHL mutation maybe a predictor of responses to immune checkpoint inhibitors (ICIs). Our research aims to elucidate its mutation association with ICI efficacy.
Methods
In order to investigate the correlation between VHL mutation and ICI efficacy in the RCC, we used cBioportal to collect clinical and mutation data of 151 ICI-treated RCCs from MSKCC cohort. Gene expression and WES data of 313 samples were obtained from the TCGA database for further analysis of potential biological mechanisms between VHL-mutant and VHL-wildtype tumors. Tumor mutation burden (TMB) was calculated as the total number of somatic non-synonymous mutations per megabase in both MSKCC and TCGA cohorts. CIBERSORT algorithm was applied to infer 22 human immune cell type proportions in TCGA RCCs.
Results
In the MSKCC immunotherapy cohort, we observed 70.2% (106/151) patients harbored VHL mutation, while TCGA had lower mutation frequency with 50.5% (158/313). As indicated by Kaplan-Meier analysis, the patients with VHL mutation had significantly better OS in the MSKCC cohort (P < 0.001, median OS: 50 months vs 26 months). This link was still existing when controlling for age, sex, ICI types, TMB and metastasis in the multivariate Cox regression analysis (P = 0.005, HR = 0.45, 95%CI = 0.26-0.78). As expected, the VHL-mutant group had higher TMB than that of the VHL-wildtype group in both the MSKCC cohort (P <0.001) and TCGA cohort (P = 0.047). Immune cell analysis showed that CD8+ T cells, CD4 naïve T cells, T follicular helper cells and Macrophage M1 cells were abundant in the VHL-mutant group (both P < 0.05). These results indicated VHL-mutant tumors had an activated antitumor immune microenvironment.
Conclusions
VHL mutations might be a potential biomarker to predict the efficacy of immunotherapy for RCC. Considering the heterogeneity among the patients and other confounding factors, further prospective validation cohorts are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23